Abstract
Purpose
So far there is no analysis available on the cost effectiveness of the paclitaxel/platinum-analogue combination versus carboplatin monotherapy with ovarian cancer. Up-to-now only a cost-utility analysis on ovarian carcinoma has been published (Ortega et al. in Gynecol Oncol 66(3):454–463, 1997), which in addition to the first-line chemotherapy included second-line chemotherapy with effectiveness and cost data in the analysis. Therefore, within the scope of our study the cost effectiveness of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-lie chemotherapy was to be determined with epithelial ovarian carcinoma.
Methods
For this purpose a decision-making Markov model was developed which represents the medical and economic consequences of the administration of paclitaxel and platinum derivatives in first-line chemotherapy and the administration of topotecan and liposomal doxorubicin in second-line chemotherapy in the treatment of epithelial ovarian carcinoma by means of data from the literature. Patients were treated either in the early (FIGO stage I–IIa) or advanced stage (FIGO stage IIb–IV).
Results
The therapeutic strategy caboplatin followed by topotecan costs 20,123.91 €, the therapeutic strategy carboplatin followed by liposomal doxorubicin 22,336.57 €, the therapeutic strategy carboplatin/pactlitaxel followed by liposomal topotecan 29,820.64 € and the therapeutic strategy carboplatin/paclitaxel followed by liposomal doxorubicin 31,560.47 € from the time of diagnosis until death or survival within 5 years. With lives saved, accordingly of 2.55, 2.70, 2.60 and 2.65 years’ costs amounted to 7,891 €, 8,270.35 €, and 11,453.62 € per year of life saved.
Conclusions
Based on the threshold value of social willingness to pay 45,500 € per year of life saved, the therapeutic strategy carboplatin followed by topotecan, the therapeutic strategy carboplatin followed by liposomal doxorubicin, the therapeutic strategy carboplatin/paclitaxel followed by topotcan and the therapeutic strategy carboplatin/paclitaxel followed by liposomal doxorubicin can be evaluated to be cost effective.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bennett CL, Golub R, Watrs TM et al (1997) Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 115:227–223
Briggs A, Sculpher M (1998) An introduction to Markov-modelling for economic evaluation. Pharmacoeconomics 13(4):397–409
Du Bois A, Nejit JP, Thigpen JT (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer—a new standard of care. Ann Oncol 10(Supl):S35–S41
Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312–3322
Gordon AN, Granai CO, Rose PG et al (2000) Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18(17):3093–3100
Guyatt GH, Sackett DL, Cook DJ (1994) Users’ guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 271:59–63
ICON 3 (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet 360:505–514
McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1–6
Muggia FM, Braly PS, Brady MF et al (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18(1):106–115
Ortega A, Dranitsaris G, Sturgeon J et al (1997) Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 66(3):454–463
Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699–708
Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making13(4):322–338
Ten Bokkel Huinink W, Gore M, Carmichael J (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15(6):2183–2193
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s00432-007-0313-y.
Rights and permissions
About this article
Cite this article
Hartmann, M., Fedders, M., Schneider, A. et al. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma. J Cancer Res Clin Oncol 133, 619–625 (2007). https://doi.org/10.1007/s00432-007-0210-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-007-0210-4